Ipamorelin and CJC-1295: Understanding This Peptide Combination
Ipamorelin and CJC-1295 are often discussed together in growth hormone-related peptide protocols. Here's how they're thought to work and what to know before considering them.
Two Peptides, Two Mechanisms
Ipamorelin is classified as a growth hormone secretagogue. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog. They act on different receptors but both relate to the body's natural growth hormone axis.
Why They Are Often Combined
Some clinicians combine GHRH analogs with secretagogues with the goal of supporting more pulsatile, physiologic patterns of growth hormone release rather than directly administering external HGH. Research on combination protocols in humans is still limited.
Important Considerations
These peptides are not FDA-approved to treat the normal aging process. They are prescription compounds and require clinical oversight, including baseline labs and monitoring. They are not appropriate for everyone.
Talk to a Licensed Provider
Anyone curious about growth hormone-related peptide therapy should review their goals and medical history with a licensed provider. This article is for educational purposes only and does not constitute medical advice.
Ready to start your wellness journey?
Get personalized treatment recommendations from licensed healthcare providers.
Find my treatment